Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...
Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) and Sanofi SA (NASDAQ:SNY) presented new, detailed results from the RELIEVE ...
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...
Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.
The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...
Short interest in Teva Pharmaceutical Industries Ltd (NYSE:TEVA ... are betting on the decline of Teva Pharmaceutical Indus's stock. Short interest data is updated every two weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback